Policy & Regulation
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evalua...
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) f...
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
3 November 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) announced on Tuesday that its Phase II NeoLIPA study evaluating ruxotemitide in combination with pembr...
Ultima Genomics UG200 Sequencing Platform selected for SG-INSIGHT study
3 November 2026 - US biotechnology company Ultima Genomics announced on Monday that its UG200 Sequencing Platform has been selected for the SG-INSIGHT study, a cohort under Phase III of Singapore'...
Fresenius and WuXi Biologics agree biosimilars development partnership
2 November 2026 - Healthcare company Fresenius SE & Co KGaA (XETR: FRE) (OTCM: FSNUY) declared on Monday that it has signed an exclusive development agreement with research, development and manufa...
POLYTECH Health & Aesthetics partners with London Regenerative Institute on adipose tissue processing in aesthetic and reconstructive surgery
2 November 2026 - POLYTECH Health & Aesthetics GmbH, a Germany-based company involved in breast aesthetics, reconstruction, and body contouring, and the London Regenerative Institute (LRI), a clin...